Clinical evaluation of a novel multipoint radiofrequency ablation device to treat chronic rhinitis
Laryngoscope Investigative Otolaryngology · 2023-04 · 8 (2) · 367-372
DOI: 10.1002/lio2.1040 ↗Kurz gefasst
Fachartikel in der Zeitschrift Laryngoscope Investigative Otolaryngology, online erschienen am 16.03.2023. Verfasst von Douglas D Reh und 6 weiteren Autor:innen. Beteiligte Einrichtung: Centers for Advanced ENT Care Baltimore Maryland USA. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objective
Safety and efficacy of the NEUROMARK® system for treating chronic rhinitis.
Methods
A prospective, single‐arm, multicenter study was performed on adults with chronic rhinitis who underwent radiofrequency ablation to the posterior nasal nerves. Primary endpoints were device‐related serious adverse events (SAEs) at 1 month and change from baseline in visual analog scale nasal symptom scale (VAS NSS) for rhinorrhea and nasal congestion at 3 months. Total nasal symptom score (rTNSS) and mini Rhinoconjunctivitis Quality of Life Questionnaire (mini RQLQ) score were also evaluated.
Results
Thirty‐six participants were enrolled and completed follow‐up at 1 and 3 months. Mean VAS NSS scores for rhinorrhea and nasal congestion demonstrated significant improvement at 3 months (both p < .0001). The mean percent changes from baseline in VAS rhinorrhea and nasal congestion were 53% and 55%, respectively. Total scores and all individual rTNSS items significantly improved (all p < .001) over the measured interval. Percent responder rate (≥30% reduction from baseline in total rTNSS) at 3 months was 78%. The total mean mini RQLQ scores, as well as all subdomains, improved significantly (all p < .0001). At 3 months, 89% of participants reported a minimal clinically important difference of ≥0.4 point improvement in the mini RQLQ score. No SAEs occurred during the study.
Conclusions
The NEUROMARK System is a novel radiofrequency ablation device that provides safe and effective treatment to the posterior nasal nerves for patients with chronic rhinitis. Study participants experienced statistically significant and clinically meaningful improvement in symptoms and quality of life assessments at 3 months post‐procedure. Trial Registration The study is registered at www.clinicaltrials.gov with the unique identifier of NCT05324397. Level of Evidence 4.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Centers for Advanced ENT Care Baltimore Maryland USA.
- Alabama Nasal and Sinus Center Birmingham Alabama USA.
- ENT and Allergy Associates Seattle and Puyallup Washington USA.
- Specialty Physician Associates Bethlehem Pennsylvania USA.
- O'Malley Medical Communications, LLC Victoria Minnesota USA.
ORCID-Profile: Ellen M O'Malley
Zitieren
APA
Reh, D. D., Lay, K., Davis, G., Dubin, M. G., Yen, D. M., O'Malley, E. M., & Sillers, M. (2023). Clinical evaluation of a novel multipoint radiofrequency ablation device to treat chronic rhinitis. Laryngoscope Investigative Otolaryngology, 8(2), 367-372. https://doi.org/10.1002/lio2.1040
Vancouver
Reh DD, Lay K, Davis G, Dubin MG, Yen DM, O'Malley EM, et al. Clinical evaluation of a novel multipoint radiofrequency ablation device to treat chronic rhinitis. Laryngoscope Investigative Otolaryngology. 2023;8(2):367-372. doi:10.1002/lio2.1040
BibTeX
@article{Reh2023,
author = {Reh, Douglas D and Lay, Kristopher and Davis, Greg and Dubin, Marc G and Yen, David M and O'Malley, Ellen M and Sillers, Michael},
title = {Clinical evaluation of a novel multipoint radiofrequency ablation device to treat chronic rhinitis},
journal = {Laryngoscope Investigative Otolaryngology},
year = {2023},
volume = {8},
number = {2},
pages = {367--372},
doi = {10.1002/lio2.1040}
}
EUVIMED